All DOT Articles
-
803ClinicalHow Safe and Effective Are Next-Generation Spectacle Lenses for Myopia Management?
March 1, 2024 By Nabin Paudel, BOptom, PhD Myopia is a growing public health concern that will affect an estimated 4.7 billion...
-
568Latest Myopia NewsSightGlass’ DOT Spectacle Lenses Receive FDA Breakthrough Device Designation
February 14, 2024 LOS ALTOS, Calif. — SightGlass Vision’s Diffusion Optics Technology (DOT) spectacle lenses have received Breakthrough Device designation from the...
-
972Latest Myopia NewsIMI Shares Updated 2023 Myopia Facts and Figures Infographic
November 9, 2023 SYDNEY, Australia — The International Myopia Institute (IMI) has released its 2023 update for the Facts and Finding Infographic....
-
657Latest Myopia NewsSightGlass Vision Releases First White Paper on DOT Lenses
September 20, 2023 LOS ALTOS, Calif. — SightGlass Vision’s Diffusion Optics Technology (DOT) spectacle lenses are the subject of a recently released...
-
671Latest Myopia NewsSightGlass Presents Four-Year Results of CYPRESS Trial at CCOS
September 5, 2023 CHANGSHA, China — At the Congress of the Chinese Ophthalmological Society (CCOS) in Changsha, SightGlass Vision shared the four-year results...
-
948Latest Myopia NewsSightGlass Vision’s DOT Spectacles Found to be Effective for Reducing Myopia Progression
October 25, 2022 LOS ALTOS, Calif. — New findings from SightGlass Vision’s three-year CYPRESS clinical trial have highlighted the efficacy of the...
-
1.4KLatest Myopia NewsSightGlass Vision Spectacles Slow Myopia Progression for 6- and 7-Year-Olds
June 23, 2022 PALO ALTO, Calif. — In analyzing two-year data from SightGlass Vision’s CYPRESS clinical trial, experts have learned that the...
-
1.5KLatest Myopia NewsSightGlass Vision Announces New Executive Team
March 24, 2022 PALO ALTO, Calif. — SightGlass Vision announced the appointment of three new leadership positions to its executive team. Andrew...